Literature DB >> 23154773

Conventional chondrosarcoma in a survivor of rhabdoid tumor: enlarging the spectrum of tumors associated with SMARCB1 germline mutations.

Fabien Forest1, Audrey David, Sandrine Arrufat, Gaelle Pierron, Dominique Ranchere-Vince, Jean-Louis Stephan, Alix Clemenson, Olivier Delattre, Franck Bourdeaut.   

Abstract

SMARCB1 germline mutations mainly predispose to rhabdoid tumors. However, less aggressive tumors with a later onset have also been reported in a context of SMARCB1 constitutional mutation-that is, schwannomatosis and meningiomatosis. No other tumor type has formally been observed in such a context thus far. We report on a patient treated for a thoracic malignant rhabdoid tumor at 8 years of age who subsequently developed a mandibular conventional chondrosarcoma at 13 years of age. Both tumors showed a loss of BAF47 expression. The malignant rhabdoid tumor exhibited a large 22q11.2 deletion and an intragenic deletion of SMARCB1 (exons 1 to 3), thus leading to a biallelic inactivation. A 2.8 Mbp deletion encompassing SMARCB1 was found in the germline. This context was a strong incentive to investigate SMARCB1 alterations in the second tumor. As expected, the chondrosarcoma showed the large 22q11.2 deletion but also an additional c.243C>G(p.Tyr18X) premature stop codon in the remaining allele. This report relates for the first time a pediatric conventional chondrosarcoma to the wide family of SMARCB1-deficient tumors. Moreover, we report here the first case of conventional chondrosarcoma arising in a context of constitutional SMARCB1 deletion and, thus, enlarge the spectrum of this tumor predisposition syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154773     DOI: 10.1097/PAS.0b013e31826cbe7a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

Review 2.  Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Authors:  William D Foulkes; Junne Kamihara; D Gareth R Evans; Laurence Brugières; Franck Bourdeaut; Jan J Molenaar; Michael F Walsh; Garrett M Brodeur; Lisa Diller
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

3.  Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.

Authors:  Santhosh A Upadhyaya; Rose B McGee; Breelyn A Wilky; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

Review 4.  Case-based review: atypical teratoid/rhabdoid tumor.

Authors:  Cody L Nesvick; Amulya A Nageswara Rao; Aditya Raghunathan; Jaclyn A Biegel; David J Daniels
Journal:  Neurooncol Pract       Date:  2018-10-05

5.  Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.

Authors:  Jilong Yang; Matti Annala; Ping Ji; Guowen Wang; Hong Zheng; David Codgell; Xiaoling Du; Zhiwei Fang; Baocun Sun; Matti Nykter; Kexin Chen; Wei Zhang
Journal:  J Hematol Oncol       Date:  2014-10-10       Impact factor: 17.388

6.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.